Efficacy and safety
| Telaprevir | Boceprevir | |
| Negative viral loads at week | ||
|---|---|---|
| 4 | 15/23 (65.22%) | 7/15 (46.67%) |
| 8 | 18/21 (85.71%) | 8/14 (57.14%) |
| 12 | 19/19 (100%) | 4/5 (80.00%) |
| 24 | 8/8 (100%) | 1/1 (100%) |
| Anaemia | ||
| Reduced dose of ribavirin | 6 (20.69%) | 6 (28.57%) |
| Treatment with erythropoiesis-stimulating agent | 2 (6.90%) | 1 (4.76%) |
| Discontinued | 1 (3.45%) | 1 (4.76%) |
| Neutropenia | ||
| Reduction dose of peginterferon-alfa | 2 (6.90%) | 4 (19.05%) |
| Treatment with granulocyte colony-stimulating factor (G-CSF) | 1 (3.45%) | 4 (19.05%) |
| Rash | ||
| Discontinued | 1 (3.45%) | 0 (0%) |